Nurix Therapeutics (NASDAQ:NRIX) PT Raised to $31.00 at Barclays
Nurix Therapeutics (NASDAQ:NRIX – Free Report) had its price objective raised by Barclays from $20.00 to $31.00 in a research report report published on Monday morning, Benzinga reports. The firm currently has an overweight rating on the stock. A number of other analysts have also recently weighed in on the stock. JPMorgan Chase & Co. […]
More Stories
Republicans Sue to Prevent Counting of Undated Ballots in Pennsylvania Senate Race
By Sam Dorman Republicans have asked the Pennsylvania Supreme Court to intervene in the state’s Senate race, alleging that several...
Insider Selling: MicroStrategy Incorporated (NASDAQ:MSTR) CAO Sells 752 Shares of Stock
MicroStrategy Incorporated (NASDAQ:MSTR – Get Free Report) CAO Jeanine Montgomery sold 752 shares of the firm’s stock in a transaction...
Head to Head Contrast: Neumora Therapeutics (NMRA) & Its Competitors
Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) is one of 295 publicly-traded companies in the “Biological products, except diagnostic” industry,...
Traders Buy High Volume of TC Energy Put Options (NYSE:TRP)
TC Energy Co. (NYSE:TRP – Get Free Report) (TSE:TRP) saw some unusual options trading activity on Wednesday. Stock investors purchased...
Traders Buy High Volume of Call Options on MongoDB (NASDAQ:MDB)
MongoDB, Inc. (NASDAQ:MDB – Get Free Report) saw unusually large options trading on Wednesday. Investors acquired 36,130 call options on...
US Households Must Earn Nearly $108,000 to Afford a Median-Priced Home: Report
By Naveen Athrappully Housing affordability has dropped considerably in major American metros, according to the latest data published by Oxford...